Novo Nordisk Wipes Out $30 Billion In Market Value After Failed Heart Drug Trial
By W.B.D. Editorial

Analysts were critical of the Ozempic maker’s failed trial for a new experimental drug.

Analysts were critical of the Ozempic maker’s failed trial for a new experimental drug.